As US review of Eli Lilly-partnered PD-1 gets underway, Innovent touts another frontline win in China
When Eli Lilly inked a $1 billion-plus deal to grab ex-China commercialization rights for Innovent’s PD-1 Tyvyt (sintilimab), the partners hailed the “clinical profile” of the drug they co-developed and vowed to keep exploring its potential across tumor types.
One year later, Tyvyt has notched another big win on its home turf.
Suzhou-based Innovent says at the interim analysis, the drug hit the primary endpoint of overall survival in ORIENT-16, a Phase III clinical trial for unresectable, locally advanced, recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. Specifically, it pits a combination of the PD-1 inhibitor and chemotherapy (oxaliplatin and capecitabine) against chemo alone.